MedTrace Logo

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

NCT05564286 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2024-02-06

No results posted yet for this study

Summary

The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly cisplatin chemotherapy in a south Chinese cohort.

Conditions

  • Cervical Cancer
  • Nasopharyngeal Cancer
  • Chemotherapy-induced Nausea and Vomiting
  • Radiation-Induced Nausea and Vomiting
  • Antiemetic

Interventions

DRUG

Fosaprepitant

In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .

DRUG

tropisetron

All patients received tropisetron 5mg on day 1.

DRUG

Dexamethasone

.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.

Sponsors & Collaborators

  • Shantou University Medical College

    lead OTHER

Principal Investigators

  • Chuangzhen Chen · Shantou University Medical College

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-07-31
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05564286 on ClinicalTrials.gov